Zimmer, one of the world’s biggest makers of orthopaedic implants, is reviewing its contracts with hundreds of US surgeons in a move that could take the company’s bill for clearing up a legal case last year to more than $450m.

Under procedures intended to make its dealings with surgeons with whom it has consultancy relationships more transparent, Zimmer is considering terminating its royalty contracts with many of these doctors.